Business, energy, technology, markets and global industry news from Business News Today

Stargardt disease

PharmaDeviceNews Stargardt disease
Representative image of RNAi drug discovery research in a biotechnology laboratory. City Therapeutics’ $99.5 million Series B financing puts next-generation RNA interference therapies, including CITY-FXI and CITY-RBP4, in sharper focus as the field expands beyond liver-targeted medicines.
Pharma & Biotech

City Therapeutics raises $99.5m as CITY-FXI and CITY-RBP4 head toward key tests

City Therapeutics has fresh capital, but RNAi’s next test is tissue delivery. See why CITY-FXI and CITY-RBP4 matter now.

Read More
Pharma & Biotech

What Ocugen, Inc.’s OCU410ST milestone means for the race to treat inherited retinal blindness

Discover what Ocugen, Inc.’s OCU410ST milestone means for the future of inherited retinal blindness treatment and the race toward first approval.

Read More
Pharma & Biotech

Can VeonGen Therapeutics validate VR-based endpoints as Stargardt trials move toward pivotal design

VG801 shows early vision gains in Stargardt disease. Find out what this means for gene therapy endpoints and regulatory pathways.

Read More
Pharma & Biotech

Tinlarebant moves closer to FDA review after Belite Bio finishes DRAGON II trial enrollment

Find out how Belite Bio’s DRAGON II milestone moves tinlarebant closer to FDA review as a potential first therapy for Stargardt disease.

Read More